Proteins for the treatment of epithelial barrier function disorders
Andrew Wonhee Han, Brisbane, CA (US); Andrew W. Goodyear, Brisbane, CA (US); Tarunmeet Gujral, Brisbane, CA (US); Todd Zachary DeSantis, Brisbane, CA (US); and Karim Dabbagh, Brisbane, CA (US)
Assigned to Genevive, Inc., San Mateo, CA (US)
Filed by Genevive, Inc., San Mateo, CA (US)
Filed on Jul. 18, 2023, as Appl. No. 18/354,372.
Application 18/354,372 is a continuation of application No. 17/526,970, filed on Nov. 15, 2021, abandoned.
Application 17/526,970 is a continuation of application No. 16/618,499, granted, now 11,174,293, issued on Nov. 16, 2021, previously published as PCT/US2018/035682, filed on Jun. 1, 2018.
Claims priority of provisional application 62/518,138, filed on Jun. 12, 2017.
Claims priority of provisional application 62/518,137, filed on Jun. 12, 2017.
Claims priority of provisional application 62/514,165, filed on Jun. 2, 2017.
Claims priority of provisional application 62/514,148, filed on Jun. 2, 2017.
Prior Publication US 2024/0076323 A1, Mar. 7, 2024
i) a protein comprising an amino acid sequence having at least about 95% sequence identity to SEQ ID NO:1, SEQ ID NO:9, SEQ ID NO:13, or SEQ ID NO:19; and
ii) a pharmaceutically acceptable carrier,
wherein the protein comprises at least one post translational modification.